KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Payables (2016 - 2026)

Bio-Rad Laboratories has reported Payables over the past 18 years, most recently at $533.6 million for Q1 2026.

  • Quarterly Payables rose 283.61% to $533.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $533.6 million through Mar 2026, up 283.61% year-over-year, with the annual reading at $130.3 million for FY2025, 5.51% up from the prior year.
  • Payables was $533.6 million for Q1 2026 at Bio-Rad Laboratories, up from $130.3 million in the prior quarter.
  • Over five years, Payables peaked at $533.6 million in Q1 2026 and troughed at $103.2 million in Q1 2024.
  • The 5-year median for Payables is $139.1 million (2025), against an average of $159.9 million.
  • Year-over-year, Payables tumbled 36.08% in 2024 and then soared 283.61% in 2026.
  • A 5-year view of Payables shows it stood at $135.5 million in 2022, then grew by 7.08% to $145.1 million in 2023, then dropped by 14.89% to $123.5 million in 2024, then grew by 5.51% to $130.3 million in 2025, then surged by 309.52% to $533.6 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Payables are $533.6 million (Q1 2026), $130.3 million (Q4 2025), and $130.1 million (Q3 2025).